A recent study indicates that people who discontinue new weight-loss injections like semaglutide or tirzepatide can put back on shed pounds much more quickly than those who halt traditional diet and exercise programs.
Findings released in a major health publication points out that while obese people frequently drop substantial amounts of their body weight while using the jabs, the mass is regained at an estimated rate of 0.8 kg per month once they quit.
"People using these treatments need to be cognizant of the danger of fast weight regain when the therapy is stopped," cautioned lead investigator Dr. Susan Jebb.
That rate of recovery implies a return to starting weight in about one and a half years.
Weighing Therapies
The analysis, which examined 37 of trials involving over 9,000 of patients, compared the results of the injectable medications with older methods.
Scientists emphasize that people who lose weight through diet and exercise usually have a less rapid creep back—approximately 100 grams monthly—once they finish.
The Reason for the Quick Regain
Experts suggest the mechanism of the jabs explains the accelerated weight return.
These medications mimic a natural hormone called glucagon-like peptide-1, which controls hunger.
"Artificially providing GLP-1 levels several times higher than the body's typical production could lead to the body to generate a reduced amount of its own natural hormone, and may also diminish responsiveness to its actions," said Dr. Adam Collins, a dietetics expert.
"Withdrawal of this GLP-1 'fix' results in appetite is uncontrolled, making excessive eating far more likely."
A Lifelong Disease?
Medical guidelines recommend the injections for people with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.
A number of clinicians say that, considering the significant potential of weight regain, the therapy might need to be life-long.
This opinion is supported by drug manufacturers, who state that the results "highlight the long-term nature of excess weight," similar to managing diseases like high blood pressure.
Patient Experiences
Users who have discontinued the medication explain a intense return of appetite.
"I experienced a trigger that goes on and I was suddenly starving," said one woman.
This challenge is exacerbated if individuals have not established permanent dietary or behavioural changes during treatment.
Significant Adoption
Survey data suggest that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with desire continuing to grow.
- Adoption is higher among women compared to men.
- The 40s and 50s demographic shows the highest level of interest.
- Many access the drugs through private prescriptions rather than public health services.
Ultimately, researchers emphasize that while GLP-1 drugs are powerful tools for weight loss, they are not a magic cure and long-term success hinges on combined behavioural support.
